# Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00989690** · PHASE3 · UNKNOWN · sponsor: **Istituto Scientifico H. San Raffaele** · enrollment: 275 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** erlotinib hydrochloride
- **DRUG:** pemetrexed disodium
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** mutation analysis
- **GENETIC:** proteomic profiling
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** matrix-assisted laser desorption/ionization time of flight mass spectrometry
- **PROCEDURE:** breath test

## Key facts

- **NCT ID:** NCT00989690
- **Lead sponsor:** Istituto Scientifico H. San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989690, "Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00989690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*